Upstream bioprocessing equipment market seen reaching $18.61B by 2030

The upstream bioprocessing equipment market is projected to grow from $11.13 billion in 2025 to $18.61 billion by 2030, driven by demand for biologics, vaccines and scalable manufacturing. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Upstream bioprocessing equipment is becoming a bigger part of biopharmaceutical manufacturing as demand rises for biologics, personalized medicines and flexible production capacity. - The market’s projected growth signals more spending on the tools that support cell culture, fermentation and early-stage drug production. - Scalable manufacturing matters because biopharma companies need to move from development to commercial production without sacrificing yield or quality.

What happened: - The Business Research Company projected the global upstream bioprocessing equipment market will rise from $11.13 billion in 2025 to $12.32 billion in 2026. - The firm said the market is expected to reach $18.61 billion by 2030. - The report puts the forecast-period CAGR at 10.9%. - The release was dated July 8, 2026.

The details: - Upstream bioprocessing equipment includes systems used early in biopharmaceutical production to cultivate microbial or mammalian cells. - The equipment supports cell line development, media preparation, cell culture and fermentation under controlled conditions. - The systems are used to help produce vaccines, monoclonal antibodies and recombinant proteins. - Historical growth was tied to rising demand for monoclonal antibodies and vaccines, higher investment in biopharmaceutical manufacturing, wider use of mammalian cell culture, growth in contract manufacturing organizations and a stronger focus on process efficiency and yield optimization. - Forecast growth is supported by a growing pipeline of biosimilars and biologics, broader use of single-use technologies, more demand for personalized medicine production, expansion of gene and cell therapy manufacturing facilities and investment in flexible biomanufacturing plants. - Key trends include single-use bioreactors, perfusion-based cell culture systems, modular upstream equipment, closed-system bioprocessing and automation in sampling and process controls. - The report said single-use bioreactors can reduce contamination risk and improve flexibility. - The report said perfusion-based cell culture systems support continuous biologics production. - The report said modular, scalable equipment can speed facility expansion. - The report said closed-system bioprocessing can improve sterility and process efficiency. - The report said automation can improve consistency. - A free sample of the report is available here. - The full report is available here.

Between the lines: - The market’s growth is being pulled by the need to scale biologics manufacturing faster and with more flexibility. - The UK biotech sector secured about $4.4 billion in investments in January 2025, according to the BioIndustry Association of the UK, up 94% from the prior year. - That funding spike points to continued demand for manufacturing infrastructure that can handle larger and more varied production pipelines. - North America held the largest market share in 2025 because of its established biopharmaceutical base. - Asia-Pacific is expected to be the fastest-growing regional market during the forecast period because of industrialization and higher healthcare investment.

What's next: - More biopharma companies are likely to invest in single-use, modular and closed-system equipment as they expand capacity. - Gene therapy, cell therapy and biosimilar manufacturing should remain key demand drivers through 2030. - The Business Research Company said its 2026 reports now include market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel dashboards, market hotspots infographics and updated trend analysis. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa.